Iron Deficiency Anemia: Ferric Maltol As a New Treatment Option- Summarization of the New Perspective

Speciality: Hematology


Speaker:

Prof. Dr. Carsten Schmidt | MA, FEBGH Department of Internal Medicine (Gastroenterology, Metabolic Diseases), Fulda Hospital

Description:

A warm welcome to all the medical professionals to this session on "Iron Deficiency Anemia: Ferric Maltol As a New Treatment Option- Summarization of the New Perspective." This session synthesizes the key takeaways from our discussion on ferric maltol, highlighting its transformative potential in the management of iron deficiency anemia (IDA). The overarching new perspective is a shift away from the traditional, one-size-fits-all approach to oral iron supplementation, toward a more nuanced and patient-focused strategy.

The primary limitation of standard oral iron salts is their high incidence of gastrointestinal (GI) side effects, which leads to poor patient adherence and treatment failure. Ferric maltol provides a new perspective by addressing this issue directly. Its unique chemical structure, a stable complex of ferric iron (Fe³⁺) and maltol, minimizes the release of free iron in the gut, thereby reducing GI irritation and inflammation. This improved tolerability is not just a secondary benefit; it is a core feature that can lead to better treatment compliance and, ultimately, more effective iron repletion.

In conclusion, the new perspective is that ferric maltol is not simply another oral iron option, but a clinically meaningful alternative that overcomes the historical drawbacks of traditional oral iron. Its proven efficacy and favorable tolerability profile, particularly in challenging patient populations like those with inflammatory bowel disease or chronic kidney disease, position it as a valuable tool in the modern management of IDA. This allows clinicians to choose a therapy that is both effective and well-tolerated from the outset, leading to a better quality of life for patients.


See More Webinars @ Hidoc Webinars





Featured News
Featured Articles
Featured Events
Featured KOL Videos

1.

Nearly 6 Million Deaths From Five Major Cancer Types Averted Since 1975

2.

Child Death Rates Are Rising in the U. s. ; Water Beads Warning; Cancer Studies Retracted.

3.

Interleukin-6 may boost prediction of obesity-related cancers

4.

Researchers use AI to monitor side effects of chemotherapy and support families dealing with pediatric cancer.

5.

As EGFR internalization is decreased, BUB1 controls EGFR signaling.


© Copyright 2025 Hidoc Dr. Inc.

Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation
bot